Evil rabbit, Thanks for your moderate approach
Post# of 155614
(Total Views: 615)
Posted On: 08/07/2021 4:50:00 PM
Re: Evil Rabbit #99129
Evil rabbit,
Thanks for your moderate approach. I believe Drs Pourhassan and Kelly have done well under trying circumstances with limited resources.
We all (witness the tables of expected mortality reduction we bandied about here late last year) expected a home run with CD12.
I believe Cytodyn expected that as well and, in retrospect could have looked more critically at Amarex and the DSMB. Despite being small, Cytodyn needs to make certain that trials are executed as they expect. Amarex and the DSMB were selected as the agents of Cytodyn to execute the trials, I expect with fiduciary responsibility. It appears to me that they did not discharge their duties appropriately. Recall the request for 42 day mortality when the main impact (associated with day 0 and 7 dosing) was at day 14. Strange.
I am entitled to my frustrations. Messaging of clinical activities and trial results are wholly the responsibility of Cytodyn. As I stated previously, the uneven rollout of CD12 results did not provide a clear picture of the clinical impact of Leronlimab. By the time the 14 days 82% reduction was released, the moment to best demonstrate the impact of Leronlimab had already been lost IMO.
I believe we are finally on the right track with the HIV BLA, but I don’t believe there is anyone who can honestly argue that messaging about the BLA RTF and resubmission has been clear.
I am pleased that Cytodyn has been able to simultaneously pursue cancer, HIV, Covid and NASH. Quite a lot for a small company.
The trials starting in Brazil look great. I have great confidence in the current team. Dr Recknor is top notch. Director Gardiner brings experience that I believe has been lacking. Amarex I believe has been supplanted by Recknor and A Einstein. Drs Pourhassan and Kelly now have the team they need.
I don’t posit here to be like, disliked, trusted or branded a traitor. I remain steadfast in my conviction that Leronlimab and modification of the innate immune / adaptive system intersection will simply transform medicine.
Those who do not like what I have to say, including my demonstration of my concerns and my occasionally crappy posts are free to block me. I certainly have blocked a few so that I can focus on the excellent insights shared by the majority of contributors here.
Thanks.
Thanks for your moderate approach. I believe Drs Pourhassan and Kelly have done well under trying circumstances with limited resources.
We all (witness the tables of expected mortality reduction we bandied about here late last year) expected a home run with CD12.
I believe Cytodyn expected that as well and, in retrospect could have looked more critically at Amarex and the DSMB. Despite being small, Cytodyn needs to make certain that trials are executed as they expect. Amarex and the DSMB were selected as the agents of Cytodyn to execute the trials, I expect with fiduciary responsibility. It appears to me that they did not discharge their duties appropriately. Recall the request for 42 day mortality when the main impact (associated with day 0 and 7 dosing) was at day 14. Strange.
I am entitled to my frustrations. Messaging of clinical activities and trial results are wholly the responsibility of Cytodyn. As I stated previously, the uneven rollout of CD12 results did not provide a clear picture of the clinical impact of Leronlimab. By the time the 14 days 82% reduction was released, the moment to best demonstrate the impact of Leronlimab had already been lost IMO.
I believe we are finally on the right track with the HIV BLA, but I don’t believe there is anyone who can honestly argue that messaging about the BLA RTF and resubmission has been clear.
I am pleased that Cytodyn has been able to simultaneously pursue cancer, HIV, Covid and NASH. Quite a lot for a small company.
The trials starting in Brazil look great. I have great confidence in the current team. Dr Recknor is top notch. Director Gardiner brings experience that I believe has been lacking. Amarex I believe has been supplanted by Recknor and A Einstein. Drs Pourhassan and Kelly now have the team they need.
I don’t posit here to be like, disliked, trusted or branded a traitor. I remain steadfast in my conviction that Leronlimab and modification of the innate immune / adaptive system intersection will simply transform medicine.
Those who do not like what I have to say, including my demonstration of my concerns and my occasionally crappy posts are free to block me. I certainly have blocked a few so that I can focus on the excellent insights shared by the majority of contributors here.
Thanks.
(27)
(0)